Fosbretabulin

Generic Name: Fosbretabulin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁O_₈P

CAS Number: 222030-63-9

Unique Ingredient Identifier: I5590ES2QZ

Background: Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Biological: Bevacizumab
Drug: Fosbretabulin Tromethamine
Other: Laboratory Biomarker Analysis

First Posted Date: 2011-02-28

Last Posted Date: 2019-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT01305213

Locations: 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸
Maine Medical Center-Bramhall Campus, Portland, Maine, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States

and more 48 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy